Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 1
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 1

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderSyndax · 61
Strongest available pathInsmed · +342.3%
Widest latest marginVertex Pharmaceuticals · 32.9%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1SNDX · Nasdaq

Syndax

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2005Waltham, Massachusetts$1.71B market cap
View full Companies Radar profile
61Moderate
Snapshot price$19.29as of page date
Monthly-close return+0.9%five-year window
FY2025 revenue$0.17BSyndax Pharmaceuticals Inc
Net margin-165.6%FY2025
P/E snapshot-23.6xone ratio, not a verdict
Prism attention2.1%share across these five
Filing track recordRevenue, USD billions
+11261.4%
$0$0.1B$0.1B$0.2BFY2020: $0.002BFY2021: $0.140BFY2022: $0.140BFY2024: $0.024BFY2025: $0.172B20202021202220242025
FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 226.5%
52-week position50% through range
$12.99$25.59
News mentions1.1K
Community mentions11partial coverage
U.S.-scope patents198
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal87/100
Management stability90/100
Market position10/100
Capital-event signal69/100
Innovation pulse23/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 4 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2VRTX · Nasdaq

Vertex Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1989Boston$137.93B market cap
View full Companies Radar profile
61Moderate
Snapshot price$544.5as of page date
Monthly-close return+200.2%five-year window
FY2025 revenue$12.00BVERTEX PHARMACEUTICALS INC / MA
Net margin32.9%FY2025
P/E snapshot31.7xone ratio, not a verdict
Prism attention18.9%share across these five
Filing track recordRevenue, USD billions
+58.4%
$0$4.0B$8.0B$12.0BFY2021: $7.574BFY2022: $8.931BFY2023: $9.869BFY2024: $11.020BFY2025: $12.001B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.2%
52-week position94% through range
$374.2$555.7
News mentions9.8K
Community mentions251partial coverage
U.S.-scope patents62
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal75/100
Management stability90/100
Market position24/100
Capital-event signal80/100
Innovation pulse22/100
Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 6 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3ABBV · NYSE

AbbVie

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2013North Chicago, Illinois$453.12B market cap
View full Companies Radar profile
60Moderate
Snapshot price$256.4as of page date
Monthly-close return+137.7%five-year window
FY2025 revenue$61.16BAbbVie Inc.
Net margin6.9%FY2025
P/E snapshot72.2xone ratio, not a verdict
Prism attention66.9%share across these five
Filing track recordRevenue, USD billions
+8.8%
$0$20.4B$40.8B$61.2BFY2021: $56.197BFY2022: $58.054BFY2023: $54.318BFY2024: $56.334BFY2025: $61.160B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.1%
52-week position86% through range
$190.8$267.5
News mentions34.8K
Community mentions5.9Kpartial coverage
U.S.-scope patents9278
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal51/100
Management stability90/100
Market position53/100
Capital-event signal89/100
Innovation pulse27/100
Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 93 M&A involvements, 20 asset-acquisition events and 30 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 9 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4ALNY · Nasdaq

Alnylam

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2002Cambridge, Massachusetts$32.21B market cap
View full Companies Radar profile
59Moderate
Snapshot price$240.7as of page date
Monthly-close return+27.5%five-year window
FY2025 revenue$3.71BALNYLAM PHARMACEUTICALS, INC.
Net margin8.4%FY2025
P/E snapshot41.9xone ratio, not a verdict
Prism attention9.1%share across these five
Filing track recordRevenue, USD billions
+127966.8%
$0$1.2B$2.5B$3.7BFY2019: $0.003BFY2020: $0.003BFY2023: $1.828BFY2024: $2.248BFY2025: $3.714B20192020202320242025
FY2019–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 498.2%
52-week position14% through range
$197.8$495.6
News mentions4.7K
Community mentions79partial coverage
U.S.-scope patents4606
Prism Insights

What sits behind the readiness signal

Observed risk 7/100higher means more observed risk
Earnings signal76/100
Management stability90/100
Market position15/100
Capital-event signal86/100
Innovation pulse25/100
Management signal

No leadership-churn flag in the model; 10 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 2 asset-acquisition events and 11 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 7 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 2 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5INSM · Nasdaq

Insmed

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1999Bridgewater, New Jersey$26.60B market cap
View full Companies Radar profile
59Moderate
Snapshot price$121.8as of page date
Monthly-close return+342.3%five-year window
FY2025 revenue$0.61BINSMED Inc
Net margin-210.5%FY2025
P/E snapshot151.8xone ratio, not a verdict
Prism attention3.0%share across these five
Filing track recordRevenue, USD billions
+221.8%
$0$0.2B$0.4B$0.6BFY2021: $0.188BFY2022: $0.245BFY2023: $0.305BFY2024: $0.364BFY2025: $0.606B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 33.9%
52-week position26% through range
$90.39$212.8
News mentions1.6K
Community mentions0partial coverage
U.S.-scope patents641
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal83/100
Management stability90/100
Market position10/100
Capital-event signal75/100
Innovation pulse13/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 1 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 4 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Insmed
+342.3%
Vertex Pharmaceuticals
+200.2%
AbbVie
+137.7%
Alnylam
+27.5%
Syndax
+0.9%

Latest revenue

USD billions, official filing scope shown on each company card.

AbbVie
$61.16B
Vertex Pharmaceuticals
$12.00B
Alnylam
$3.71B
Insmed
$0.61B
Syndax
$0.17B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Vertex Pharmaceuticals
32.9%
Alnylam
8.4%
AbbVie
6.9%
Syndax
-165.6%
Insmed
-210.5%

Prism news attention

Normalized share across these five names; attention is not quality.

AbbVie
66.9%
Vertex Pharmaceuticals
18.9%
Alnylam
9.1%
Insmed
3.0%
Syndax
2.1%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

AbbVie leads the conversation

It holds 66.9% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $61.16B.

Price path

Insmed leads the available price paths

Its monthly-close return is +342.3% for the five-year window. At the other end, Syndax is +0.9% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Vertex Pharmaceuticals has the widest latest margin

Its FY2025 net margin is 32.9%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Syndax shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -23.6x while its five-year window price return is +0.9%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · SNDX

Syndax

1,067available Prism news records

Prism top themes

Price action & investor response
88
Earnings & financial performance
46
Capital allocation & transactions
31
Legal, arbitration & regulatory
17
Leadership & governance
8

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-24.5%166 latest 12m vs 220 prior 12m
2024-01: 5 mentions2024-02: 13 mentions2024-03: 13 mentions2024-04: 5 mentions2024-05: 15 mentions2024-06: 13 mentions2024-07: 11 mentions2024-08: 20 mentions2024-09: 10 mentions2024-10: 13 mentions2024-11: 41 mentions2024-12: 7 mentions2025-01: 17 mentions2025-02: 60 mentions2025-03: 10 mentions2025-04: 15 mentions2025-05: 13 mentions2025-06: 3 mentions2025-07: 6 mentions2025-08: 14 mentions2025-09: 21 mentions2025-10: 16 mentions2025-11: 15 mentions2025-12: 13 mentions2026-01: 9 mentions2026-02: 19 mentions2026-03: 14 mentions2026-04: 19 mentions2026-05: 13 mentions2026-06: 7 mentions2024-012026-06

Machine-classified coverage tone

98.7% positive+6.7 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 22stock performance 22share price 19gene therapy rare diseases 12rare disease treatment 11leukemia driver mutations 11cytogenetic abnormalities leukemia 6phase iii trial 6

Keyword tag occurrences in available Prism news records.

Coverage: 2010-05-24–2026-06-13 · trend and themes shown through 2026-06
Areas of research · VRTX

Vertex Pharmaceuticals

9,834available Prism news records

Prism top themes

Price action & investor response
430
Capital allocation & transactions
223
Macro demand & rates
187
Earnings & financial performance
144
Legal, arbitration & regulatory
70

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-1.9%1,529 latest 12m vs 1,558 prior 12m
2024-03: 95 mentions2024-04: 170 mentions2024-05: 138 mentions2024-06: 105 mentions2024-07: 114 mentions2024-08: 103 mentions2024-09: 64 mentions2024-10: 118 mentions2024-11: 96 mentions2024-12: 139 mentions2025-01: 250 mentions2025-02: 243 mentions2025-03: 107 mentions2025-04: 116 mentions2025-05: 171 mentions2025-06: 85 mentions2025-07: 60 mentions2025-08: 109 mentions2025-09: 164 mentions2025-10: 101 mentions2025-11: 101 mentions2025-12: 94 mentions2026-01: 171 mentions2026-02: 268 mentions2026-03: 158 mentions2026-04: 221 mentions2026-05: 204 mentions2026-06: 44 mentions2026-07: 2 mentions2026-08: 1 mentions2024-032026-08

Machine-classified coverage tone

91.2% positive+6.6 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 274crispr-cas9 212crispr applications 194stock performance 128cell-based therapies 100rare disease clinical trials 95stem cell banking 88non-opioid analgesics 85

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-08-01 · trend and themes shown through 2026-08
Areas of research · ABBV

AbbVie

34,821available Prism news records

Prism top themes

Price action & investor response
1,565
Capital allocation & transactions
583
Legal, arbitration & regulatory
574
Earnings & financial performance
561
Macro demand & rates
356

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+13.6%5,525 latest 12m vs 4,862 prior 12m
2024-02: 416 mentions2024-03: 306 mentions2024-04: 382 mentions2024-05: 420 mentions2024-06: 408 mentions2024-07: 335 mentions2024-08: 327 mentions2024-09: 260 mentions2024-10: 358 mentions2024-11: 362 mentions2024-12: 271 mentions2025-01: 462 mentions2025-02: 890 mentions2025-03: 417 mentions2025-04: 452 mentions2025-05: 374 mentions2025-06: 262 mentions2025-07: 427 mentions2025-08: 450 mentions2025-09: 551 mentions2025-10: 478 mentions2025-11: 426 mentions2025-12: 418 mentions2026-01: 606 mentions2026-02: 696 mentions2026-03: 418 mentions2026-04: 837 mentions2026-05: 455 mentions2026-06: 189 mentions2026-07: 1 mentions2024-022026-07

Machine-classified coverage tone

87.4% positive+2.2 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

generic drug approval 319stock performance 186orphan drug pricing 152angiogenesis inhibitors 146earnings report 137stock price 133adc therapeutics 133private equity 116

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-12 · trend and themes shown through 2026-07
Areas of research · ALNY

Alnylam

4,713available Prism news records

Prism top themes

Price action & investor response
412
Capital allocation & transactions
278
Earnings & financial performance
88
Legal, arbitration & regulatory
38
Leadership & governance
31

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+1.0%684 latest 12m vs 677 prior 12m
2024-03: 39 mentions2024-04: 35 mentions2024-05: 32 mentions2024-06: 53 mentions2024-07: 21 mentions2024-08: 40 mentions2024-09: 20 mentions2024-10: 49 mentions2024-11: 42 mentions2024-12: 8 mentions2025-01: 36 mentions2025-02: 288 mentions2025-03: 69 mentions2025-04: 42 mentions2025-05: 32 mentions2025-06: 27 mentions2025-07: 17 mentions2025-08: 47 mentions2025-09: 101 mentions2025-10: 67 mentions2025-11: 35 mentions2025-12: 53 mentions2026-01: 77 mentions2026-02: 69 mentions2026-03: 61 mentions2026-04: 51 mentions2026-05: 47 mentions2026-06: 122 mentions2026-07: 0 mentions2026-08: 1 mentions2024-032026-08

Machine-classified coverage tone

90.8% positive+4.6 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 123stock performance 112investment deal 94company valuation 43orphan drug pricing 36rare disease treatment 35angel investors 33gene delivery systems 32

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-08-02 · trend and themes shown through 2026-08
Areas of research · INSM

Insmed

1,562available Prism news records

Prism top themes

Price action & investor response
191
Earnings & financial performance
56
Capital allocation & transactions
54
Legal, arbitration & regulatory
42
Macro demand & rates
29

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+43.4%436 latest 12m vs 304 prior 12m
2024-01: 8 mentions2024-02: 18 mentions2024-03: 12 mentions2024-04: 12 mentions2024-05: 39 mentions2024-06: 12 mentions2024-07: 9 mentions2024-08: 7 mentions2024-09: 10 mentions2024-10: 9 mentions2024-11: 11 mentions2024-12: 6 mentions2025-01: 12 mentions2025-02: 152 mentions2025-03: 22 mentions2025-04: 11 mentions2025-05: 22 mentions2025-06: 33 mentions2025-07: 11 mentions2025-08: 33 mentions2025-09: 20 mentions2025-10: 22 mentions2025-11: 30 mentions2025-12: 50 mentions2026-01: 68 mentions2026-02: 50 mentions2026-03: 26 mentions2026-04: 59 mentions2026-05: 54 mentions2026-06: 13 mentions2024-012026-06

Machine-classified coverage tone

94.0% positive+10.5 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 50stock price 22share price 21investment deal 13stock surge 10angel investors 10stock indices 7earnings per share 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-15–2026-06-29 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

VRTX

Vertex Pharmaceuticals

251 mentions
Stock and valuation
109
Products, pricing and logistics
34
Workplace and hiring
6

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 251 records remained after filtering.

ABBV

AbbVie

5,881 mentions
Products, pricing and logistics
2,224
Stock and valuation
1,354
Workplace and hiring
219
Other company context
23

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 5,881 records remained after filtering.

ALNY

Alnylam

79 mentions
Stock and valuation
36
Products, pricing and logistics
14
Workplace and hiring
3

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 79 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

SNDX

Syndax

through 2026-05-01
Earnings releases 32Company announcements 31Leadership changes 8Listing / IPO 6Regulatory 3
  1. Earnings releases

    Chief Financial Officer Keith Goldan said total revenue was $64.9 million in the quarter, up 224% year-over-year.

  2. Company announcements

    Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted inducement awards to purchase up to 15,500 shares of common stock to one new employee under the Company's 2023 Inducement Plan.

  3. M&A

    KBC Group NV boosted its position in shares of Syndax Pharmaceuticals by 104.8% in the fourth quarter. KBC Group NV now owns 6,954 shares of the company’s stock worth $92,000 after acquiring an additional 3,559 shares during the last quarter.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VRTX

Vertex Pharmaceuticals

through 2026-05-05
Earnings releases 48Leadership changes 19Company announcements 11M&A 5Business contracts 4
  1. Earnings releases

    Chief Operating Officer and Chief Financial Officer Charlie Wagner said total revenue rose 8% year over year to $2.99 billion, with non‑GAAP EPS was $4.47 compared with $4.06 in the prior‑year quarter.

  2. Board updates

    termination of Mr. Upadhyay's service on our board of directors

  3. Company announcements

    Vertex realized its goal for greater than $100 million of CASGEVY revenue in 2025, reflecting more than 60 patients receiving infusions of CASGEVY.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ABBV

AbbVie

through 2026-04-17
Earnings releases 79M&A 38Leadership changes 19Lawsuits 17Business contracts 15
  1. Earnings releases

    AbbVie increased its revenue over 8% to $61 billion for the year.

  2. Lawsuits

    The Seventh Circuit affirmed the dismissal of a False Claims Act (FCA) retaliation suit against AbbVie Inc. (formerly Allergan) brought by former sales representative Jeffrey Lewis.

  3. Company announcements

    AbbVie announced on Monday (13), in São Paulo, the expansion of its investment in clinical research in Brazil.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ALNY

Alnylam

through 2026-03-10
Earnings releases 43Leadership changes 10Company announcements 9Listing / IPO 6Lawsuits 5
  1. Company announcements

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET.

  2. Earnings releases

    For the full year 2025, the company reported a net income of roughly $314 million on revenue of about $3.71 billion.

  3. Leadership changes

    Previously, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer, and Principal Financial Officer of Alnylam Pharmaceuticals, Inc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

INSM

Insmed

through 2026-02-19
Earnings releases 23Company announcements 5Listing / IPO 4Lawsuits 3Regulatory 3
  1. Earnings releases

    Insmed reported a net loss of $1,276.8 million, or $6.42 per share, compared to a net loss of $913.8 million, or $5.57 per share, for full-year 2025.

  2. Company announcements

    Insmed Soars After Raising $650 million

  3. Lawsuits

    the settlement of their patent fight over drugs for insulin-like growth factor 1 deficiency is not only taking Insmed Inc.'s Iplex off the market for short stature - decisively clearing the path for Tercica Inc. (along with licensor Genentech Inc.) to market Increlex - but also provides opt-in possibilities that continue their relationship in other indications.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 1–8. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Syndax has the widest attention-readiness rank gap

It ranks #5 by measured news attention (2.1%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Syndax in Companies Radar

Alnylam shows a price-operating divergence to inspect

Its displayed filing-revenue change is +127966.8% while its available monthly-close return is +27.5%. This is the basket's largest numerical spread; the measures use different units and windows and are not directly equivalent.

Open Alnylam in Companies Radar
Explanations

Attention measures coverage volume, not quality

AbbVie's 66.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open AbbVie in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Syndax's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 61/100 score.

Open Syndax in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon